在腹腔透析中优化氨酸血管酶抑制剂的使用:加拿大单一中心质量改善研究
Meera Shah1, Arti Dhoot1,2, Christopher Gayowsky2,3
1Division of Nephrology, University of Toronto, Toronto, ON, Canada.
概括
使用"PD护照"的质量改进倡议在腹腔透析 (PD) 患者中增加了17%的氨酸-血管激素系统抑制剂 (RASi) 使用. 这种增强的RASi利用改善了符合指导方针的护理,而不会影响患者的安全.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 改善临床质量 改善临床质量
- 药理学 药理学是指药理学的学科.
背景情况:
- 氨酶系统抑制剂 (RASi) 对于保持脏功能和腹膜完整性至关重要 腹透析 (PD) 患者.
- 在PD患者中RASi的临床使用往往受高卡莱米亚和低血压的担忧所限制.
- 优化RASi处方对于改善PD患者的治疗结果至关重要.
研究的目的:
- 在多伦多一家学术医院的符合条件的PD患者中,将RASi的利用率提高20%.
- 评估质量改进计划对RASi处方率的影响.
- 通过监测血压和水平来评估增加RASi利用的安全性.
主要方法:
- 进行了回顾性图表审查,以确定基线RASi利用率 (2022年7月-2023年9月).
- 实施了"PD护照"临床文档工具,以识别和解决患者访问期间错过的RASi处方机会.
- 主要结局是实施后6个月RASi利用率的变化,其中包括护照完成率和低血压和高血的平衡措施.
主要成果:
- 在63名PD患者中,基线RASi利用率为41%.
- 在实施"PD护照"后,RASi的使用率增加到59%,增长了17%,远远低于20%的目标.
- 在干预之前和之后,没有观察到平均静脉压,血清水平或尿液输出的显著变化,这表明患者的安全性得到维持.
结论:
- "PD护照"计划显著提高了17%的PD患者的RASi利用率,没有对血压或水平产生不良影响.
- 这种结构化文档方法有效地弥合了基于证据的指导方针和PD患者的临床实践之间的差距.
- 像"PD护照"这样的有针对性的质量改进工具对于提高指导方针一致的护理和优化PD药物使用是有价值的.
相关概念视频
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.3K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K
01:20Acute Kidney Injury V: Interprofessional Care
297
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
297
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
936
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
936
01:28Chronic Kidney Disease III: Interprofessional Care
344
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
344
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
260
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
260
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
209
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
209